High blood pressure affects nearly half of U.S. adults, making it one of the country’s most common chronic health conditions.
Over the past several decades, advances in clinical research have changed how doctors treat hypertension, leading to medications that are more effective, better tolerated, and more likely to reduce the risk of heart attack, stroke, and kidney disease.
As a result, many older blood pressure medications are no longer recommended as first-line treatment for most people. That doesn’t mean they no longer work. In many cases, they still play an important role for certain patients or specific medical conditions. But newer therapies often provide similar or better blood pressure control with fewer side effects or stronger evidence for long-term cardiovascular protection.
Here are 12 older blood pressure medications that clinicians now use less frequently as initial treatment—and the newer options that have largely taken their place.
IMPORTANT: Never stop or change a prescribed blood pressure medication without talking to your healthcare provider. A medication that is no longer considered first-line treatment may still be the safest and most effective choice for your individual medical situation.
Methyldopa
Methyldopa is an old first‑line treatment for hypertension. A meta‑analysis of 12 trials involving 595 patients showed that methyldopa lowered systolic blood pressure by about 13 mmHg and diastolic by about 8 mmHg compared with placebo. However, none of those trials assessed mortality or primary cardiovascular outcomes. Over the decades, concerns about sedation, dry mouth, depression, and severe liver injury surfaced.
Because of these risks and the availability of better‑tolerated drugs, methyldopa is now very rarely used for general hypertension, reserved mainly for specific scenarios, such as in pregnancy, when other options are limited. Indeed, its side‑effect profile and monitoring requirements make it less practical.
Reserpine
Reserpine used to play an essential role in the management of hypertension. A Cochrane review described reserpine as “effective in reducing systolic blood pressure roughly to the same degree as other first‑line antihypertensive drugs.” However, this effect was mild to moderate, and the adverse‑effect data were limited.
Its central nervous system effects, including depression and fatigue, combined with newly available drugs that had more favorable side effect profiles, made it less appealing. Although some older analyses found it effective in lowering systolic pressure by ~8 mmHg compared with a placebo. However, that came with trade‑offs in tolerability and less robust evidence in modern settings. Thus, it is now rarely used except perhaps in very resistant cases and under specialist supervision.
Guanethidine
Guanethidine is another older antihypertensive that was once widely used. It works by blocking sympathetic nerve endings and markedly reducing peripheral vascular resistance. But the problem: it comes with a heavy burden of side‑effects — severe orthostatic hypotension (feeling faint on standing), drug interactions, and inconvenient dosing.
Modern practice has phased it out because safer, more predictable alternatives are now available. The frequency of its adverse effects and the complexity of its administration have made it an outdated choice in routine practice.
Oral Clonidine
Oral clonidine stays on the radar but is now mainly limited to particular situations, such as hypertensive emergencies, rather than the long-term management of hypertension. It does cause significant rebound hypertension if stopped abruptly and can cause sedation and dry mouth.
In the management of everyday hypertension, it is not favored due to its superior safety, lower rebound risk, and more substantial evidence of efficacy. Thus, oral clonidine is an outdated scenario for maintenance therapy.
Hydralazine (monotherapy)
Hydralazine as monotherapy has lost favor in general hypertension care. The long-standing data on hydralazine alone provide limited evidence of long-term outcomes. The first-line agents emphasized in the 2025 AHA/ACC guideline include ACE inhibitors, ARBs, long-acting calcium-channel blockers, and thiazide-type diuretics.
Hydralazine alone is poorly effective and has a higher rate of side effects, for instance, reflex tachycardia and a lupus-like syndrome, as stated by the National Institutes of Health. Today, it is used almost exclusively in combination with other drugs or in very specialized settings, such as in pregnant patients for specific indications, rather than as first or second line.
Oral Minoxidil
Minoxidil (oral) is indeed a potent vasodilator. Still, it presents major drawbacks to the treatment of hypertension, including severe fluid retention, heart-rate increase, and even hair growth.
In light of this fact, due to the availability of better-tolerated and better-studied drugs, oral minoxidil is reserved only for very resistant hypertension that has failed other options. For routine management, it is now considered outdated due to its risk-to-benefit ratio.
Prazosin
Prazosin is an older alpha‑blocker. It was used for hypertension control. Still, now it is mainly used for other indications, such as for prostate enlargement or PTSD‑related nightmares, instead of the general management of blood pressure.
Why? The alpha‑blockers did not fare as well in trials conducted for the reduction in cardiovascular outcomes when considered with other classes, and they tend to cause orthostatic hypotension and other side effects. So in the contemporary treatment of hypertension, prazosin is seldom used and is considered outdated.
Doxazosin
Doxazosin is another alpha‑blocker that fell out of favor. The landmark trial ALLHAT showed that doxazosin increased the risk of heart failure compared with a diuretic. In particular, ResearchGate found that the risk of CHF was twofold higher (RR ≈ 2.04; 95% CI 1.79–2.32) with doxazosin as first‑line versus chlorthalidone.
Save this article
Enter your email address and we'll send it straight to your inbox.
Because of that risk, and because other classes now dominate first‑line care, namely ACE inhibitors, ARBs, thiazides, and long‑acting Ca‑channel blockers, this drug is rarely used for hypertension alone. Modern guidelines explicitly discourage alpha‑blocker monotherapy for hypertension except in limited cases.
Terazosin
Terazosin is similar to doxazosin in its class and limitations, except that it also carries a risk of orthostatic hypotension, has less robust outcome data, and is now mainly used in conditions such as benign prostatic hypertrophy.
Given the better alternatives, its role in modern hypertension therapy is minimal. It has become one of those older drugs that almost always get bypassed in favor of newer, more proven ones.
Propranolol
Propranolol is a nonselective beta-blocker that was once a staple for hypertension. However, in the most recent guidelines, beta-blockers are no longer first-line for hypertension unless there is a compelling indication, such as heart failure or post-myocardial infarction.
A 2020 meta-analysis by the National Institutes of Health found that beta-blockers were less protective for stroke and all-cause death when compared to other antihypertensive classes. Nonselective beta-blockers have more side effects compared to newer cardioselective agents. Thus, propranolol is outdated mainly in the standard management of hypertension.
Atenolol
Another older beta‑blocker that is commonly used is atenolol. Studies found the regimens based on atenolol were less effective at reducing stroke risk when compared with other drugs: one meta‑analysis showed a relative risk of stroke of 1.26 (95% CI 1.15‑1.38) compared with other antihypertensives.
Because of that and due to the availability of better-tolerated beta‑blockers, its role has greatly diminished. Modern guidelines use it only when specific conditions exist. This makes atenolol one of those medications that used to be typical but is now rarely the best choice.
Nifedipine (short‑acting)
Nifedipine (short‑acting), especially the immediate‑release version, is now strongly discouraged for hypertension management. A meta‑analysis reported that short‑acting nifedipine was linked to increased mortality, particularly at doses > 80 mg daily and in patients with coronary disease.
The risk of rapid blood‑pressure drops and associated cardiovascular events was concerning. Current practice favors long‑acting formulations of dihydropyridine calcium‑channel blockers over short‑acting ones. Thus, the short‑acting nifedipine has become outdated for this indication.
Key Takeaway
Modern care for hypertension has changed. The 2025 AHA/ACC guideline emphasizes early initiation of therapy and selection of first‑line drugs, including ACE inhibitors, ARBs, long‑acting calcium‑channel blockers, and thiazide‑type diuretics.
Generally, the following 12 are now considered obsolete for the general treatment of high blood pressure: methyldopa, reserpine, guanethidine, oral clonidine, hydralazine used as monotherapy, oral minoxidil, prazosin, doxazosin, terazosin, propranolol, atenolol, and short‑acting nifedipine. Most are used only in niche settings or when specific conditions require them.
More articles:
- Why modern healthcare is making so many Americans delay seeing a doctor
- The Best and Worst States for Elderly Healthcare
- Living with IBS: What Patients and Healthcare Providers Are Saying
These 11 hidden costs of aging are financially crushing many older Americans
The years meant for rest and reward are revealing a harsher truth—growing older in America now comes with a price few people planned for.
Retirement used to look like an endless vacation on a sunny golf course. Today’s older Americans are waking up to a totally different reality. The golden years are starting to feel a bit tarnished by financial strain and surprise expenses. Many folks are realizing that their lifelong plans might need a serious overhaul. Learn more.
Therapy is trending, but not all of it is helpful. 11 red flags you shouldn’t ignore
Therapy culture exploded because millions of Americans are finally talking about mental health, but the internet is blurring the line between healing and harm.
Therapy is everywhere right now. It is in your TikTok feed, on your favorite podcast, stitched into memes, and quietly living in the group chat. That is not an accident. In 2024, more than one in five U.S. adults, about 61.5 million people, lived with a mental illness, according to new data from the Substance Abuse and Mental Health Services Administration. Learn more.
